Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.48 |
| ▸ | NOS1 | P29475 | 8/20 | 0.44 |
| ▸ | NOS2 | P35228 | 8/20 | 0.44 |
| ▸ | NOS3 | P29474 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160970 | 0.83 | TAAR1 (0.57) | LOXL2NOS1SMN1; SMN2CYP3A4NFKB1 | |
| SCHEMBL15981410 | 0.83 | ENPP2 (0.50) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL27938953 | 0.83 | PNMT (0.45) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL1908544 | 0.80 | CYP1A2 (0.45) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7162484 | 0.78 | TRPA1 (0.42) | ALDH1A1MGAMACHE | |
| SCHEMBL8861632 | 0.78 | MGAM (0.47) | ENPP2NOS1NOS2NOS3MGAM | |
| SCHEMBL27608831 | 0.78 | LOXL2 (0.46) | PNMTENPP2LOXL2NOS1NOS2 | |
| Methylamine SCHEMBL28040876 | 0.77 | PNMT (0.40) | PNMTENPP2LOXL2NOS1NOS2 | |
| Bromide SCHEMBL8345607 | 0.77 | MGAM (0.39) | MGAMACHE | |
| SCHEMBL5470508 | 0.77 | HRH3 (0.50) | LOXL2NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | PNMT 1712/4885ENPP2 1482/4885LOXL2 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.